Document is current
Any future updates will be listed below
-
Authors
Bonaventura, Aldo https://orcid.org/0000-0002-4747-5535
Vecchié, Alessandra
Dagna, Lorenzo
Martinod, Kimberly https://orcid.org/0000-0002-1026-6107
Dixon, Dave L.
Van Tassell, Benjamin W.
Dentali, Francesco
Montecucco, Fabrizio https://orcid.org/0000-0003-0823-8729
Massberg, Steffen https://orcid.org/0000-0001-7387-3986
Levi, Marcel
Abbate, Antonio
- License Information
-
More Information
Article History
Accepted: 9 March 2021
First Online: 6 April 2021
Competing interests
: A.B. and A.V. received a travel grant from Kiniksa Pharmaceuticals Ltd and honoraria from Effetti s.r.l. (Milan, Italy). L.D. has received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, GlaxoSmithKline, Novartis, Pfizer, Roche, Sanofi-Genzyme and SOBI. K.M. is an inventor on patent US9642822 and patent applications WO20180271953A1 and US2019167680A1, and is a consultant for PEEL Therapeutics, Inc. B.W.V.T. has served as a consultant for Novartis and Serpin Pharma, and has received research support from Novartis, Kiniksa Pharmaceuticals Ltd, Serpin Pharma and SOBI. A.A. has served as a consultant for Applied Clinical Intel, AstraZeneca, Cromos Pharma, Janssen, Kiniksa Pharmaceuticals Ltd, Merck, Olatec and Serpin Pharma, and has received research support from Janssen, Olatec and Serpin Pharma. All other authors declare no competing interests.
Free to read: This content has been made available to all.
